AU2020235358A1 - Bacterium of the Christensenellaceae Family For The Prevention And/Or Treatment Of Chronic Inflammatory Diseases And/Or Inflammatory Gastrointestinal Diseases And/Or Cancers - Google Patents
Bacterium of the Christensenellaceae Family For The Prevention And/Or Treatment Of Chronic Inflammatory Diseases And/Or Inflammatory Gastrointestinal Diseases And/Or Cancers Download PDFInfo
- Publication number
- AU2020235358A1 AU2020235358A1 AU2020235358A AU2020235358A AU2020235358A1 AU 2020235358 A1 AU2020235358 A1 AU 2020235358A1 AU 2020235358 A AU2020235358 A AU 2020235358A AU 2020235358 A AU2020235358 A AU 2020235358A AU 2020235358 A1 AU2020235358 A1 AU 2020235358A1
- Authority
- AU
- Australia
- Prior art keywords
- christensenella
- bacterium
- composition
- use according
- inflammatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 169
- 238000011282 treatment Methods 0.000 title claims description 40
- 230000002757 inflammatory effect Effects 0.000 title claims description 35
- 208000037976 chronic inflammation Diseases 0.000 title claims description 30
- 241000755889 Christensenellaceae Species 0.000 title claims description 22
- 208000018522 Gastrointestinal disease Diseases 0.000 title claims description 22
- 208000037893 chronic inflammatory disorder Diseases 0.000 title claims description 20
- 230000002265 prevention Effects 0.000 title claims description 18
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 title claims description 15
- 241000755920 Christensenella Species 0.000 claims description 134
- 239000000203 mixture Substances 0.000 claims description 105
- 102000004890 Interleukin-8 Human genes 0.000 claims description 37
- 108090001007 Interleukin-8 Proteins 0.000 claims description 37
- 229940096397 interleukin-8 Drugs 0.000 claims description 35
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims description 35
- 241001254467 Christensenella timonensis Species 0.000 claims description 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 241000702462 Akkermansia muciniphila Species 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 29
- 230000001580 bacterial effect Effects 0.000 claims description 25
- 241000282414 Homo sapiens Species 0.000 claims description 22
- 102000004889 Interleukin-6 Human genes 0.000 claims description 22
- 108090001005 Interleukin-6 Proteins 0.000 claims description 22
- 241000914543 Christensenella massiliensis Species 0.000 claims description 21
- 229940100601 interleukin-6 Drugs 0.000 claims description 21
- 239000012228 culture supernatant Substances 0.000 claims description 18
- 102000003814 Interleukin-10 Human genes 0.000 claims description 17
- 108090000174 Interleukin-10 Proteins 0.000 claims description 17
- 241000702460 Akkermansia Species 0.000 claims description 16
- 229940076144 interleukin-10 Drugs 0.000 claims description 16
- -1 ispension Substances 0.000 claims description 12
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 12
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 12
- 208000011231 Crohn disease Diseases 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 10
- 241000282412 Homo Species 0.000 claims description 9
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 7
- 239000006041 probiotic Substances 0.000 claims description 7
- 235000018291 probiotics Nutrition 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 235000013406 prebiotics Nutrition 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 5
- 235000016709 nutrition Nutrition 0.000 claims description 5
- 230000000529 probiotic effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000002389 Pouchitis Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 239000005557 antagonist Substances 0.000 claims description 3
- 208000010668 atopic eczema Diseases 0.000 claims description 3
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 3
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 230000004083 survival effect Effects 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 102000003951 Erythropoietin Human genes 0.000 claims description 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 2
- 241000186394 Eubacterium Species 0.000 claims description 2
- 241001608234 Faecalibacterium Species 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000266824 Oscillospira Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 239000000150 Sympathomimetic Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000007513 acids Chemical class 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 239000003263 anabolic agent Substances 0.000 claims description 2
- 229940070021 anabolic steroids Drugs 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 claims description 2
- 230000003178 anti-diabetic effect Effects 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 230000003474 anti-emetic effect Effects 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 230000000767 anti-ulcer Effects 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 239000000935 antidepressant agent Substances 0.000 claims description 2
- 229940005513 antidepressants Drugs 0.000 claims description 2
- 239000003793 antidiarrheal agent Substances 0.000 claims description 2
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 2
- 239000002111 antiemetic agent Substances 0.000 claims description 2
- 229940125683 antiemetic agent Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000000164 antipsychotic agent Substances 0.000 claims description 2
- 229940005529 antipsychotics Drugs 0.000 claims description 2
- 239000003435 antirheumatic agent Substances 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 239000002249 anxiolytic agent Substances 0.000 claims description 2
- 230000000949 anxiolytic effect Effects 0.000 claims description 2
- 229940005530 anxiolytics Drugs 0.000 claims description 2
- 229940125388 beta agonist Drugs 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 229960001334 corticosteroids Drugs 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 229960003530 donepezil Drugs 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 229940105423 erythropoietin Drugs 0.000 claims description 2
- 239000002834 estrogen receptor modulator Substances 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000122 growth hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000003326 hypnotic agent Substances 0.000 claims description 2
- 230000000147 hypnotic effect Effects 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 239000008141 laxative Substances 0.000 claims description 2
- 229940125722 laxative agent Drugs 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims description 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000012217 radiopharmaceutical Substances 0.000 claims description 2
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 2
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 230000001975 sympathomimetic effect Effects 0.000 claims description 2
- 229940064707 sympathomimetics Drugs 0.000 claims description 2
- 229960001685 tacrine Drugs 0.000 claims description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229940127225 asthma medication Drugs 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 description 32
- 206010061218 Inflammation Diseases 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 230000003110 anti-inflammatory effect Effects 0.000 description 27
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 26
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 23
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 23
- 230000000694 effects Effects 0.000 description 21
- 239000006228 supernatant Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 18
- 238000000034 method Methods 0.000 description 18
- 241000801624 Christensenella minuta Species 0.000 description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 244000005709 gut microbiome Species 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 230000006020 chronic inflammation Effects 0.000 description 10
- 210000001072 colon Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000002519 immonomodulatory effect Effects 0.000 description 8
- 235000013372 meat Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 241000736262 Microbiota Species 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 6
- 102000003896 Myeloperoxidases Human genes 0.000 description 6
- 108090000235 Myeloperoxidases Proteins 0.000 description 6
- 241001183271 Verrucomicrobiaceae Species 0.000 description 6
- 210000002919 epithelial cell Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 230000000968 intestinal effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108020004465 16S ribosomal RNA Proteins 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 208000010643 digestive system disease Diseases 0.000 description 5
- 230000002550 fecal effect Effects 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 102000042567 non-coding RNA Human genes 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 3
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 3
- 102000019298 Lipocalin Human genes 0.000 description 3
- 108050006654 Lipocalin Proteins 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000000528 statistical test Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 2
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241001112695 Clostridiales Species 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 210000004955 epithelial membrane Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 2
- 229960002737 fructose Drugs 0.000 description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003870 intestinal permeability Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 238000012316 non-parametric ANOVA Methods 0.000 description 2
- 238000001151 non-parametric statistical test Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001156739 Actinobacteria <phylum> Species 0.000 description 1
- 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 1
- 241000947856 Aeromonadales Species 0.000 description 1
- 229940126638 Akt inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000947840 Alteromonadales Species 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 241000605059 Bacteroidetes Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 208000005024 Castleman disease Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 241001430149 Clostridiaceae Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241001609975 Enterococcaceae Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000605980 Faecalibacterium prausnitzii Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 description 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 description 1
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010017531 Interleukin-16 Receptors Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- 241001112693 Lachnospiraceae Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000203065 Methanobacteriaceae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- 208000007218 Mungan syndrome Diseases 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 241000266823 Oscillospira guilliermondii Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000692845 Rikenellaceae Species 0.000 description 1
- 241000095588 Ruminococcaceae Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000005499 Sasa Species 0.000 description 1
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000131694 Tenericutes Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241001430183 Veillonellaceae Species 0.000 description 1
- 241001261005 Verrucomicrobia Species 0.000 description 1
- 241000230320 Verrucomicrobiales Species 0.000 description 1
- 241001531197 [Eubacterium] hallii Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000020827 calorie restriction Nutrition 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 208000010353 central nervous system vasculitis Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000007382 columbia agar Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 229930182497 flavan-3-ol Natural products 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003197 protein kinase B inhibitor Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a bacterium of the
Description
Description
[0001] The invention relates to the prevention and treatment of chronic inflammatory
diseases, inflammatory gastrointestinal diseases and/or cancers with specific bacteria of
the intestinal microbiota and compositions thereof.
[0002] Inflammation is the body's normal defense process against aggression. It makes it
possible to fight and eliminate the foreign agent(s) at the origin of the said aggression.
This inflammation, known as acute, is reversible and has only a limited duration ranging
from a few minutes to a few days. However, in some cases the inflammatory process goes
wrong and the inflammation becomes chronic. Instead of contributing to the body's
defense, the actors involved in the inflammatory process become dangerous and lead to
an often serious and disabling pathological condition. Chronic inflammatory diseases are therefore diseases whose pathophysiology is directly linked to inflammation, said
inflammation being of autoimmune and/or auto-inflammatory origin.
[0003] All organs can be affected by chronic inflammation, such as the digestive system
(Crohn's disease, ulcerative colitis, autoimmune gastritis, etc.), the liver (hepatitis, NAFLD,
non-alcoholic steatohepatitis, etc.), pancreas (pancreatitis), lungs (asthma), skin (atopic
dermatitis such as psoriasis), nervous system (multiple sclerosis), joints (polyarthritis).
Moreover, chronic inflammation is also present in other situations where other
mechanisms are involved, such as cancer in particular.
[0004] Chronic inflammation, and in particular chronic inflammatory diseases, affect a
large portion of the population, in varying proportions depending on the pathology
concerned. The consequences for health are important, because these diseases, although
slowly evolving, are disabling, painful and associated with a high risk of early mortality.
[0005] Currently, the treatments proposed for these diseases are anti-inflammatory drugs, immunomodulators and/or immunosuppressants. We can cite for example:
- non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen and aspirin
which are intended for short-term use and which are unsuitable for chronic pain, - purine metabolism modulators which are immunomodulators, such as
methotrexate and azathioprine,
- biological drugs such as anti-TNF-a, antagonists of the IL1 and IL6 receptors, or even - sulfasalazine.
[0006] All of these drugs have very variable response rates due to the degradation of the molecules when they are administered and have significant side effects. In addition, immunomodulators interfere with the normal and healthy immune response to pathogens, so that treated patients are susceptible to infections. As for methotrexate, it is specifically known for its adverse effects on sperm production and therefore on fertility. Thus, most of these inflammatory diseases go untreated or without adequate treatment.
[0007] Therefore, the study and research of new anti-inflammatory treatment strategies constitute a major focus in medicine and biomedical research, in particular the development of an effective treatment of chronic inflammatory diseases, gastrointestinal diseases and diseases induced by chronic inflammation, which are easy to administer and which have no side effects.
[0008] This is the objective of the present invention, which, in order to meet it, aims at the use of particular bacteria of the human intestinal microbiota, namely bacteria of the Christensenellaceae family, preferably of the genus Christensenella. These bacteria can optionally be combined with other bacteria and, in particular, bacteria of the species Akkermansia muciniphila. Bacteria of the Christensenellaceae family, in particular of the genus Christensenella, have already been studied and described. This is the case, in particular, with Christensenella minute, Christensenella massiliensis and Christensenella timonensis. Christensenella minute, in particular, was first described in 2012. In 2014, a study showed that it was the most heritable taxon in a cohort of British twins and that their presence is associated with a low body mass index. This correlation between Christensenella minute and low body mass index was then observed in ten studies published since 2014 in geographically diverse populations.
[0010] The advantage of re-establishing a minimum population of Christensenella in individuals exhibiting an inflammatory intestinal disease linked to a deficiency of Christensenella in the intestinal microbiota was disclosed in application W02016/156527. However, none of the aforementioned bacteria demonstrated a direct link with these pathologies in humans.
[0011] Furthermore, applications W02018/162738 and W02018/162726 teach that the use of particular bacteria of the Christensenellaceaefamily, belonging to species defined as being specifically distant from those of the genus Christensenella and, in particular, of the species Christensenella minute and Christensenella timonensis, make it possible to fight, in particular, against overweight and obesity by intervening, for example, on the presence of visceral fat and on intestinal permeability.
[0012] Akkermansia muciniphila, belonging to the Verrucomicrobiaceae family and the genus Akkermansia, is a bacterium identified for the first time in 2004 and which represents approximately 1to 3% by number of the total of the bacterial genera of the intestinal microbiota of healthy adults (Derrien et al., 2004, 54: 1469-1476; Derrien et al. Applied Environmental Microbiology 2008, 74, 1646-1648).
[0013] The population in number of Akkermansia muciniphila has already been reported to be reduced in stool samples from obese individuals and patients with inflammatory gastrointestinal disease (Png, et al. Gastroenterol. 2010;105: 2420-2428). Akkermansia muciniphila is associated with a healthier metabolic state and better clinical outcomes after calorie restriction intervention in overweight or even obese adults.
[0014] Surprisingly, and according to the invention, bacteria of the genus Christensenella, and in particular the species Christensenella minute, Christensenella massiliensis and Christensenella timonensis, when administered to humans or animals, are capable of acting on the markers of inflammation at the origin of inflammatory diseases, in particular inflammatory gastrointestinal diseases and chronic inflammatory diseases; and cancers. In addition, the inventors, unexpectedly determined synergistic anti-inflammatory properties resulting from the use of a bacterium of the genus Christensenella in association with a bacterium of the genus Akkermansia, in particular Akkermansia muciniphila, a new generation probiotic (NGP) well known from the Verrucomicrobiaceae family.
[0015] Therefore, the invention relates to a bacterium of the genus Christensenella, for its use in the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers in humans or animals.
[0016] Advantageously, such a bacterium, when it is administered to a human being or an animal exhibiting chronic inflammation, is capable of acting on the molecules produced in excess during chronic inflammation such as kynurenine, interleukin 6, interleukin 8, TNFalpha, interleukin 1b, lipocalins or fecal calprotectin, and/or by stimulating the production of the anti-inflammatory cytokine interleukin 10.
[0017] The invention also relates to compositions comprising at least one bacterium of the genus Christensenella, alone or in combination with at least one additional bacterium, preferably at least one additional bacterium of the genus Akkermansia, for its use in the prevention and/or the treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers in humans or animals.
[0018] Such a composition comprising, in a physiologically acceptable medium, at least one of these bacteria (at least one bacterium of the genus Christensenella alone or in combination with at least one additional bacterium of the genus Akkermansia) and/or their supernatant, is also targeted per se.
[0019] Other characteristics and advantages will emerge from the detailed specification and the figures of the invention which will follow.
[0020] BRIEF DESCRIPTION OF THE DRAWINGS
[0021] FIG. 1 shows the production of interleukin-8 (IL-8) (in pg/mL) (ordinate) in HT-29 cells stimulated by TNF-a in the presence of strains of Christensenella minuta, Christensenella timonensis, Akkermansia muciniphila, Christensenella minute
+ Akkermansia muciniphila and Christensenella timonensis + Akkermansia muciniphila (abscissa).
[0022] FIG. 2 shows the secretion of IL-8 by the intestinal cells of the HT29 line after co incubation in the presence of supernatants of strains of Christensenella minute (DSMZ: DSM22607) and stimulation by TNF-a. Dunn's nonparametric statistical test: *p<0.05; **p<0.01; ***p<0.001. IL-8: Interleukin 8; TNF-a: Tumor Necrosis Factor alpha.
Means of 4 experiments repeated in triplicates.
[0023] FIG. 3 shows the measurement of the transepithelial resistance on intestinal cells of the Caco-2 line after co-incubation in the presence of Christensenellaminute bacteria (DSMZ: DSM22607) and after stimulation with TNF-a. Dunn's nonparametric statistical test: *p<0.05; **p<0.01; ***p<0.001. IL-8: Interleukin 8; TNF-a: Tumor Necrosis Factor alpha. Means of 3 experiments repeated in triplicates.
[0024] FIG. 4 shows the effects of Christensenella minute (DSM 22607) on an inflammation model induced by DNBS. (A) Monitoring of the weight loss of the treated groups from the day of the injection (OJ).(B)Significant decrease in macroscopic scores indicating a reduction in the severity of inflammation following DSM 22607 and SASA treatments. Immunomodulatory effects of DSM22607 through the decrease in the activity of myeloperoxidase (C) and the increase of interleukin-10 (IL-10), an anti-inflammatory cytokine, in the spleen (D). Nonparametric ANOVA followed by Dunn's statistical test: *p<0.05; **p<0.01; ***p<0.001. DNBS: Dinitrobenzene sulfonic acid.
[0025] FIG. 5 demonstrates the generalization of the anti-inflammatory effects of the species of Christensenella minute on a model of inflammation induced by DNBS. (A) Reduction in macroscopic scores indicating a reduction in the severity of inflammation following treatments with different species of Christensenella minuta. (B) Immunomodulatory effects of different species of Christensenella minute through the decrease in myeloperoxidase activity (C). Nonparametric ANOVA followed by Dunn's statistical test: *p<0.05; **p<0.01; ***p<0.001. DNBS: Dinitrobenzene sulfonic acid.
[0026] FIG. 6 shows the effect of the supernatants of the strains of Christensenella minute (DSMZ: DSM22607, C. minute 1and C. minute 2) on the proliferation of HT-29 cells (adenocarcinoma of the colon). RLU: Relative Luminescence Unit. Dunnett's test where the control group is the GAM group (which represents the Gifu Anaerobic Broth culture medium). Code: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
[0027] DEFINITIONS
[0028] Within the meaning of the invention, the term "bacteria" is also understood to mean the term "bacterial strains". A bacterial strain should be understood as being a bacterium of a given strain belonging to a particular species, for example the species Christensenella minuta. Mention may be made, for example, of the bacterial strain or bacterium Christensenella minute DSM22607. Thus, the two terms can be used interchangeably to designate one or several bacteria in the context of the invention.
[0029] Within the meaning of the invention, "hyperproduction of interleukin 6" is understood to mean an excessive production of interleukin 6 relative to the production in a healthy person or animal without inflammation.
[0030] Within the meaning of the invention, "hyperproduction of interleukin 8" is understood to mean an excessive production of interleukin 8 relative to the production in a healthy person or animal without inflammation.
[0031] Within the meaning of the invention, "under-production of interleukin 10" is understood to mean an insufficient production of interleukin 10 relative to the production in a healthy person or animal without inflammation.
[0032] Within the meaning of the invention, "chronic inflammatory disease" is understood to mean, in particular, any chronic disease whose slowly and gradually evolving pathophysiology is directly related to inflammation of autoimmune and/or auto- inflammatory origin.
[0033] Within the meaning of the invention, "inflammatory gastrointestinal disease" is understood to mean, in particular, an inflammatory bowel disease, more particularly an inflammatory bowel disease of the colon. Said colonic inflammatory bowel disease can, in particular, be selected from the group consisting of Crohn's disease (CD), ulcerative colitis (UC) and pouchitis, in particular CD and UC. CD and UC are two diseases characterized by inflammation of the lining of part of the digestive tract, linked to an overactive digestive immune system.
[0034] Within the meaning of the invention, "prevent" or "prevention" are understood to mean the reduction to a lesser degree of the risk or the probability of occurrence of a given phenomenon, i.e., in the context of the present invention, chronic inflammation, gastrointestinal inflammation and pathologies resulting therefrom such as cancer, in particular intestinal inflammation.
[0035] Within the meaning of the invention, "treat" or "treatment" are understood to mean a decrease in the progression of the disease, a stabilization, a reversal or regression, or even an interruption or inhibition of the progression of an inflammatory chronic disease, an inflammatory gastrointestinal disease, cancer. In the context of the invention, these terms also apply to one or more symptoms of said diseases of the present invention.
[0036] Within the meaning of the invention, "non-deficient in Christensenella" in the intestinal microbiota is understood to mean a human being or an animal whose bacteria of the genus Christensenella in their intestinal microbiota represents at least 0.01% by number of the total of the bacterial genera detected in their intestinal microbiota, in particular at least 0.1%, and preferably at least 0.5%. Collected in the stool, the abundance of Christensenella may, for example, be measured by a quantitative sequencing test, fluorescent in situ hybridization (FISH), qPCR (quantitative PCR) or by metagenome analyzes (relative quantification), well known to a person skilled in the art.
[0037] Within the meaning of the invention, "physiologically acceptable medium" is understood to mean a medium which is compatible with the organism of the individual to which said composition is to be administered. It may be, for example, a non-toxic solvent such as water. In particular, said medium is compatible with oral administration.
[0038] Within the meaning of the invention, "microbiota" is understood to mean all the microorganisms that have colonized an individual and with which he cohabits: bacteria for the most part, but also viruses, fungi, yeasts and protozoa. The composition of the microbiota differs depending on the colonized surfaces: we thus distinguish the cutaneous microbiota, the vaginal microbiota, the urinary microbiota, the respiratory microbiota, the ENT (otorhinolaryngology) microbiota and the intestinal microbiota, formerly called the intestinal flora, by far the most important with its 100,000 billion germs. Thus, "intestinal microbiota" is understood to mean all the microorganisms, in particular bacteria, which inhabit the intestine of a given individual.
[0039] According to an official definition of the World Health Organization (WHO), "body mass index" (BMI) is understood to mean the indicator of the health risks associated with excessive weight and insufficient weight. BMI is calculated by dividing an individual's weight (in kilograms) by their height (in meters) squared. A BMI value is associated with a specific body size according to the classification given by the WHO (https://www.who.int/features/factfiles/obesity/facts/en/).
[0040] "Effective amount", "effective amount to", "amount ofXeffectivefor" and thelike, refer to an amount of an active ingredient which is effective to relieve, or to some extent reduce, one or more of the symptoms of the disease in need of treatment, or to delay the onset of clinical markers or symptoms of a disease which need prevention, when the compound is administered. Thus, the amount refers to an amount of the active ingredient which exhibits effects such as (i) reversing the rate of progression of a disease, (ii) inhibiting to some extent the progression of the disease, and/or, (iii) relieve to some extent (or, preferably, eliminating) one or more symptoms associated with the disease. The effectiveness of the amount may be determined empirically by testing the relevant compounds in known in vivo and in vitro model systems for a disease requiring treatment.
[0041] DETAILED DESCRIPTION OF THE INVENTION
[0042] The subject matter of the invention is therefore the use, in the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers, in particular cancers of an inflammatory nature, in human beings or animals, of at least one bacterium of the Christensenellaceae family, preferably of the genus Christensenella or a composition comprising at least one such bacterium and/or a culture supernatant of at least said bacterium of the genus Christensenella. The bacterium may be any bacterial strain of one of the species of the genus Christensenella. Preferably, said composition further comprises an additional bacterium of the Verrucomicrobiaceae family and/or a culture supernatant of said additional bacterium, in particular said bacterium being of the genus Akkermansia, more particularly of the Akkermansia muciniphila species.
[0043] Bacteria according to the invention.
[0044] Therefore, the invention relates to a bacterium of the Christensenellaceae family, in particular of the genus Christensenella for its use in the prevention and/or treatment of inflammatory diseases, preferably of chronic inflammatory diseases and/or of inflammatory gastrointestinal diseases and/or cancer in humans or animals, in particular in people or animals with an inflammatory disease or cancer with hyperproduction of interleukin 6 and/or hyperproduction of interleukin 8 and/or underproduction of interleukin 10.
[0045] According to the invention, bacteria of the genus Christensenella, when administered to a human being or an animal exhibiting chronic inflammation, gastrointestinal inflammation or cancer, are capable of acting on the molecules produced in excess during chronic inflammation, gastrointestinal inflammation or cancer, in particular on interleukin 6, interleukin 8 and kynurenine, but also on TNFalpha, interleukin 1b, lipocalins or fecal calprotectin. Thus, the inventors have discovered that bacteria of the genus Christensenella have the unexpected ability to reduce in vitro and in vivo inflammation and cell proliferation, in particular gastrointestinal inflammation and more particularly chronic inflammation of the intestine. More particularly, the bacteria according to the present invention are capable of significantly reducing the production of pro-inflammatory molecules, such as interleukin 6 (IL-6) and interleukin 8 (IL-8).
[0046] Indeed, in inflammatory diseases and cancers which present an increase in one of these markers such as interleukin 6, interleukin 8, kynurenine, TNFalpha, interleukin 1b, lipocalin or calprotectin, their decrease is a sign of the reduction of the pro-inflammatory signal pathway, that is to say that the immune cells responsible for this production are less stimulated. As a result, the excessive immune reaction causing the inflammation is slowed down and the system gradually returns to normal.
[0047] According to one embodiment, the bacterium or bacteria useful according to the invention are administered to humans or animals in an amount effective for an action on at least one of these markers of inflammation, that is to say to decrease the production of at least one of these molecules in the body. According to a suitable embodiment, the bacterium or bacteria may be administered at a dose of 107 to 10" colony-forming units (CFU) per day, regardless of the weight of the person or the animal, preferably a dose of 109 to 1012 CFU per day, more preferably a dose equal to 109 CFU. In particular, the dose comprises at least one bacterium selected from Christensenella timonensis, Christensenella minuta, Christensenella massiliensis and/or their mixtures. Preferably, it is a single dose, i.e., administered all at once or a dose before each meal, i.e., three times a day.
[0048] Preferably, the bacterium of the Christensenellaceae family, in particular of the genus Christensenella, is useful in the treatment of at least one chronic inflammatory disease selected from chronic inflammatory diseases of the intestine, chronic inflammatory diseases of the liver, chronic inflammatory diseases of the pancreas, polyarthritis, atopic dermatitis, neuroinflammatory diseases of the chronic obstructive pulmonary disease. In particular, it has an effect in the prevention and/or treatment of at least one disease selected from Crohn's disease, ulcerative colitis, pouchitis, ulcerative colitis, celiac disease, autoimmune gastritis, hepatitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, pancreatitis, rheumatoid arthritis, psoriatic arthritis, psoriasis, eczema.
[0049] In addition, the bacterium of the Christensenellaceae family, in particular of the genus Christensenella, is useful in the treatment of at least one inflammatory gastrointestinal disease such as an inflammatory bowel disease, more particularly an inflammatory colonic bowel affection. For the purposes of the invention, the term "affection" is understood to mean a disease or pathology. Said inflammatory bowel affection in particular may be selected from the group consisting of Crohn's disease, ulcerative colitis and pouchitis, in particular from the group consisting of Crohn's disease and ulcerative colitis.
[0050] In addition, the bacterium of the Christensenellaceaefamily, in particular of the Christensenella genus, is useful in the treatment of a proliferative disease selected from lymphomas, glioblastomas, myelomas, leukemias, colorectal cancers, cancers of the breast, prostate, ovary, uterus, pancreas, lungs, liver, gallbladder and kidneys.
[0051] The bacterium or bacteria useful according to the invention are bacteria of the genus Christensenella. It may in particular be Christensenellamassiliensis, Christensenella timonensis, Christensenella intestinihominis, and/or Christensenella minuta. According to a particularly suitable variant, it is Christensenella minuta.
[0052] These bacteria may be isolated from human stool, for example according to the protocols published by Morotomi et al. 2012 (Morotomi, M., Nagai, F. & Watanabe, Y. Description of Christensenella minute gen. nov., Sp. nov., Isolated from human faeces, which forms a distinct branch in the order Clostridiales, and proposal of
Christensenellaceae fam. nov. INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY 62, 144-149 (2012)) and NDongo et al. 2016 (Ndongo, S.,
Dubourg, G., Khelaifia, S., Fournier, P.E. & Raoult, D. Christensenella timonensis, a new
bacterial species isolated from the human gut. New Microbes and New Infections 13, 32 33 (2016)). These documents also describe the culturing methods of bacteria useful
according to the invention.
[0053] Optionally, said bacteria are available and accessible in the collection of
microorganisms and cell cultures [possible missing text] German GmbH, in particular
under filing numbers DSM 22607, DSM 102344, DSM 102800.
[0054] Composition according to the invention.
[0055] The bacterium or bacteria useful according to the invention, for their use described
above, are preferably administered in a composition, said composition comprising, in a
physiologically acceptable medium, at least the useful bacterium or bacteria and/or their
supernatant.
[0056] Thus, the invention also relates to a composition comprising at least one bacterium
of the genus Christensenella in the prevention and/or treatment of chronic inflammatory
diseases and/or inflammatory gastrointestinal diseases and/or cancers, in humans or
animals, preferably in humans or animals exhibiting hyperproduction of interleukin 6.
[0057] In particular, the invention makes it possible to provide an effective amount of
bacteria of the Christensenellaceae family, such as Christensenella massiliensis,
Christensenella timonensis, Christensenella intestinihominis and/or Christensenella
minute, for use in the treatment of:
- diseases associated with increased interleukin 6 such as an inflammatory
disorder, allergic disorder, autoimmune disorder, transplant rejection disorder, atherosclerosis, osteoporosis, neuropathic pain, sepsis, Castleman's disease, a
fibrotic condition, rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic
arthritis, osteoarthritis, refractory rheumatoid arthritis, chronic non-rheumatoid arthritis or ankylosing spondylitis,
- diseases associated with an increase in interleukin 8 such as atopic dermatitis, osteoarthritis, rheumatoid arthritis, inflammatory bowel disease, Crohn's
disease, ulcerative colitis, stroke, septic shock, endotoxic shock, psoriasis, gram
negative sepsis, toxic shock syndrome, renal reperfusion injury, glomerulonephritis, thrombosis, graft versus host reaction, allograft rejection, malaria, restenosis, angiogenesis, atherosclerosis, osteoporosis, gingivitis and unwanted release of hematopoietic stem cells, diseases caused by respiratory viruses, herpes virus and hepatitis viruses, meningitis, herpetic encephalitis, CNS vasculitis, traumatic brain injury, CNS tumors, subarachnoid hemorrhage, post surgical trauma, cystic fibrosis, pruritus, interstitial pneumonia, hypersensitivity, crystalline arthritis, Lyme arthritis, progressive ossifying fibrodysplasia, acute and chronic pancreatitis, necrotizing enterocolitis, chronic sinusitis, uveitis, polymyositis, vasculitis, acne, gastric and duodenal ulcers, celiac disease, lupus, and/or
- diseases associated with a decrease in interleukin 10 or which can be treated by
increasing interleukin 10 such as autoimmune diseases, rejection of organ and
bone marrow transplants, graft versus host disease, parasitic infections,
granulomas, Crohn's disease, colitis, pancreatitis, inflammatory lung disease,
inflammatory eye disease, atopic dermatitis and rhinitis.
[0058] According to one embodiment, the invention relates to a composition for its use
in the treatment and/or prevention of chronic inflammatory diseases and/or
inflammatory gastrointestinal diseases and/or cancers in a human being or an animal, said
composition comprising, in a physiologically acceptable medium (i) at least one bacterium
of the genus Christensenella, and/or (ii) a culture supernatant of at least one bacterium
of the genus Christensenella.
[0059] The present invention also relates to a composition for its use in the treatment
and/or prevention of an inflammatory gastrointestinal disease in an individual, said
composition comprising, in a physiologically acceptable medium
(i) at least one bacterial strain selected from the group consisting of
Christensenella timonensis, Christensenella minuteand/or their mixtures, and/or
(ii) a culture supernatant of at least any one of these bacterial strains and/or their
mixtures.
[0060] According to any one of the preceding embodiments, the present composition may
be administered to a human being suffering from chronic inflammatory diseases and/or
inflammatory gastrointestinal diseases and/or cancers, said human being having a body
mass index (BMI) less than 25, in particular said composition is administered to a human
being suffering from inflammatory gastrointestinal diseases.
[0061] The term "BMI less than 25" denotes a BMI strictly less than 25, more particularly a BMI less than or equal to 24.9. According to anyone of these embodiments, said human being may, in particular, have a BMI less than 25 and greater than or equal to 18.5.
[0062] Preferably, said composition according to the invention is characterized in that the bacterium of the genus Christensenella is selected from Christensenella massiliensis, Christensenella timonensis and/or Christensenella minute and/or Christensenella intestinihominis and/or their mixtures. It may be, in particular, a mixture of Christensenella massiliensis and Christensenella timonensis or Christensenella massiliensis and Christensenella minute or Christensenella massiliensis and Christensenella intestinihominis or Christensenella timonensis and Christensenella minute or Christensenella timonensis and Christensenella intestinihominis or Christensenella minute and Christensenella intestinihominis or Christensenella massiliensis, Christensenella timonensis and Christensenella minute or Christensenella massiliensis, Christensenella timonensis and Christensenella intestinihominis or Christensenella timonensis and Christensenella minute and Christensenella intestinihominis or Christensenella massiliensis, Christensenella minute and Christensenella intestinihominis or Christensenella massiliensis, Christensenella timonensis and Christensenella minute and Christensenella intestinihominis.
[0063] According to any one of the preceding embodiments, the composition may be used in an individual not deficient in Christensenella in the intestinal microbiota, in particular in a human being or an animal whose genus Christensenella represents at least 0.01% in number of the total of the bacterial genera of their intestinal microbiota.
[0064] The bacterium or bacteria are present in an effective amount in the composition providing an effect on chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers which are affecting the persons or animals treated. The term "person" is understood to mean an individual, in particular a human being or an animal.
[0065] Preferably, the composition useful according to any one of the preceding embodiments comprises 106 to 1012 colony-forming units (CFU) of bacteria of the genus
Christensenella per daily dose of said composition to be administered. Preferably, this corresponds to a daily dose of bacteria to be administered, regardless of the weight of the person or animal. Preferably, this dose is administered once per day. In particular, the useful composition comprises 10' to 10" CFU bacteria of the genus
Christensenella per daily dose to be administered, preferably 109 CFU. In particular, said bacteria present in the composition may be of the same species, a mixture of species or a mixture of bacterial strains. The composition useful according to the invention may be in liquid form. It may, in particular, comprise bacteria of the Christensenellaceae family, in particular of the genus Christensenella and/or a culture medium for said bacteria which makes it possible to preserve them, such as, for example, preferably the anaerobic Columbia agar medium enriched with sheep blood, or an equivalent medium not containing any animal by-product. For the purposes of the present invention, the term "culture medium" means the culture supernatant in which the bacteria or bacterial strains have resided during their culture, or extracellular medium.
[0066] According to one variant, the composition useful according to the invention may be in solid form. In this case, the bacteria may be present inlyophilized form, and may also include excipients such as, for example, microcrystalline cellulose, lactose, sucrose, fructose, levulose, starches, stachyose, raffinose, amylum, calcium lactate, magnesium sulfate, sodium citrate, calcium stearate, polyvinylpyrrolidone, maltodextrin, galactooligosaccharides, fructooligosaccharides, pectins, beta-glucans, lactoglobulins, isomaltooligosaccharides, polydextroses, sorbitol and/or glycerol.
[0067] The compositions useful according to the invention may be in the form of powder, microencapsulated powder, gelatin capsule, capsule, tablet, lozenge, granules, emulsion, suspension, suppository, a beverage, a food, pharmaceutical or nutraceutical product, a food additive, dietary supplement or dairy product.
[0068] According to a particularly suitable embodiment, the compositions may be in a gastro-resistant form, such as a coated tablet containing microencapsulated bacteria. Said composition may thus be provided with a coating resistant to gastric juice in order to ensure that the bacteria of the invention included in said composition can pass through the damaged stomach. The release of the bacterium or bacteria can thus occur for the first time in the upper intestinal tract.
[0069] More particularly, the composition according to the invention may be included in a food supplement. A food supplement for oral administration may be present in capsules, hard capsules, soft capsules, tablets, sugar-coated tablets, pills, pastes, lozenges, gums, oral solutions or emulsions, a syrup or gel.
[0070] A food supplement according to the present invention may further comprise a sweetener, a stabilizer, an antioxidant, an additive, a flavoring agent and/or a coloring agent. The formulation thereof is carried out by means of the usual methods for producing sugar-coated tablets, capsules, gels, hydrogels for controlled release, emulsions, tablets or capsules.
[0071] A composition according to the present invention may also be in the form of a nutritional composition. Such a nutritional composition according to the present invention is in the form of yogurt, cereal bar, breakfast cereal, dessert, frozen food, soup, pet food, liquid suspension, powder, tablet, gum or a piece of candy.
[0072] A composition according to the present invention may further comprise at least one ingredient selected from: antioxidants, fish oils, DHA, EPA, vitamins, minerals, phytonutrients, a protein, a lipid, probiotics and combinations thereof. The bacteria according to the invention, alone or included in the composition according to any one of the preceding embodiments, may be used in a live, semi-active, inactivated, or dead form, preferably in a living form. The semi-active, inactivated or dead form of said bacteria may be achieved, for example, by irradiation, thermal inactivation orlyophilization, in particular by heat, exposure to an appropriate pH, UV, gamma rays, X-rays or high pressure. Thus, the term "semi-active" designates a bacterium with low physiological activity whose ability to proliferate is reduced, temporarily or permanently. The term "inactivated" designates a bacterium which is no longer able, temporarily or permanently, to proliferate. The term "dead" designates a bacterium which is no longer able, definitively, to proliferate. Dead or inactivated bacteria may have intact or ruptured cell membranes. Thus, the term "inactivated" also designates the extracts and lysates of resultant bacteria.
[0073] A bacterium according to the invention, alone or in the composition according to the invention, may be used in whole form, i.e., essentially in its native form, or in the form of extracts or lysates comprising fractions and/or metabolites of this microorganism. Such a lysate may denote the whole of the lysate obtained by lysis or only a fraction thereof and may be prepared according to one of the conventional methods well known to a person skilled in the art such as, for example, a thermal shock, ultrasound, osmotic shock, or under mechanical stress, such as by centrifugation. They may all be live, semi-active, inactivated or dead. In particular, it may be a mixture of live, semi-active, inactivated and dead bacteria.
[0074] Preferably, at least some of the bacteria are live, in particular at least 50% (by number), even more preferably at least 90% (by number).
[0075] Thus, according to a suitable embodiment, at least 50% (in number) of the bacteria present in the composition useful according to the invention are living bacteria, preferably at least 90% (in number) are living bacteria, even more preferably are all living bacteria.
[0076] The storage conditions for liquid formulations according to the invention are in the form of frozen products maintained at -20 °C in sealed packets. For solid formulations, the storage conditions according to the invention comprise a capsule or a coating hermetic to light and to oxygen, maintained at an ambient temperature of between 15 °C and 40 °C and a humidity content of between 3% and 70%.
[0077] A composition according to any one of the preceding embodiments is provided for the digestive tract, in particular the intestine. Consequently, the bacteria useful according to the invention, and in particular the compositions comprising the same, may be administered by oral, topical, inhaled or rectal route, preferably rectal or intrarectal.
[0078] In particular, rectal or intrarectal administration is carried out in the form of a suppository, an enema or a foam.
[0079] The inventors have also determined, surprisingly, the ability of Christensenella strains to increase the anti-inflammatory properties of an Akkermansia strain and, in particular, of the Akkermansia muciniphila strain. Thus, the inventors demonstrated the existence of a synergistic effect of a combination of a Christensenella strain (or a culture supernatant of such a strain) and an Akkermansia strain (or a culture supernatant of such a strain) on the prevention and/or treatment of gastrointestinal inflammation, and in particular the synergistic effect of a combination of a Christensenella minute and/or Christensenella timonensis strain (or culture supernatants of such strains) and an Akkermansia muciniphila strain (or a supernatant of such strain) on the prevention and/or treatment of gastrointestinal inflammation.
[0080] Thus, according to any one of the preceding embodiments, the composition may further comprise:
(i) at least one additional bacterium of the Verrucomicrobiaceae family; and/or (ii) a culture supernatant of said additional bacterium.
[0081] Preferably, the additional bacterium of the Verrucomicrobiaceae family is a bacterium of the genus Akkermansia, more particularly of the species Akkermansia muciniphila. Within the meaning of the invention, a bacterium of the species "Akkermansia muciniphila" is also understood to mean the bacterium called
"Akkermansia muciniphila".
[0082] According to one embodiment, the bacterium and the additional bacterium as mentioned above are, independently of one another, in a live, semi-active, inactivated and/or dead form, and are in particular in a living form.
[0083] In certain embodiments, a composition according to the invention is suitable for the administration of a daily dose representing from 107 to 10" colony forming units (CFU), preferably a daily dose equivalent to 109 CFU, of a bacterium of the Verrucomicrobiaceae family, in particular of the genus Akkermansia, more particularly of an Akkermansia muciniphila bacterium.
[0084] In the case of the use of a culture supernatant of any one of the aforementioned bacteria, a composition according to the invention may, in particular, comprise a content of between 0.1 and 99% by weight, in particular from 10 to 90% by weight, in particular from 25 to 70% by weight and, more particularly, from 30 to 50% by weight, relative to the total weight of the composition.
[0085] Thus, a composition according to any one of the aforementioned embodiments may comprise a content of between 0.1 and 99% by weight, in particular from 10 to 90%, in particular from 25 to 70% by weight, more particularly from 30 to 50% by weight of supernatant relative to the total weight of the composition.
[0086] The compositions useful according to the invention, in addition to the bacteria useful according to the invention, may comprise at least one probiotic, and/or at least one prebiotic.
[0087] The compositions useful according to the invention, in addition to the bacteria useful according to the invention, may comprise other compounds, such as: - at least one probiotic, and/or
- at least one bacterium producing lactic acid which makes it possible to create an anaerobic environment favorable to Christensenellaceae, such as at least one bacterium selected from bacteria of the genus Lactobacillus spp., Bifidobacterium spp., Streptococcus spp. and/or at least one other organism promoting the anaerobic conditions necessary for the survival of Christensenellaceae, such as at least one yeast selected from Saccharomyces spp. or microorganisms of the Methanobacteriaceae family and/or - at least one bacterium associated with the ecosystem of Christensenellaceae because they facilitate their survival in the intestine, such as at least one bacterium selected from bacteria of the phylum Firmicutes, Bacteroidetes, Actinobacteria, Tenericutes, and Verrucomicrobia, and/or - at least one bacterium selected from bacteria of the order Clostridales, Verrucomicrobiales, Aeromonadales, Alteromonadales, ML615J-28, RF32, YS2, of the Clostridiaceae family, Lachnospiraceae, Ruminococcaceae, Bacteroidaceae, Enterococcaceae, Rikenellaceae, Dehalobacteriaceae, Veillonellaceae and/or - at least one bacterium selected from bacteria of the genus Faecalibacterium, Akkermansia, Eubacterium and Oscillospira such asfor example Faecalibacterium prausnitzii, Akkermansia muciniphila, Eubacterium halii, Oscillospira guilliermondii, and/or - at least one prebiotic such as, for example, at least one prebiotic selected from galactooligosaccharides, fructooligosaccharides, inulins, arabinoxylans, beta glucans, lactoglobulins and/or beta-caseins, and/or - at least one polyphenol such as, for example, at least one polyphenol selected from quercetin, kaempferol, resveratrol, flavones (such as luteolin), flavan-3-ols (such as catechins), flavanones (such as narinenin), isoflavones, anthocyanidins, proanthocyanidins, and/or - at least one mineral and/or at least one vitamin and/or at least one nutritional agent, and/or - at least one active pharmaceutical principle preferably selected from non steroidal anti-inflammatory drugs, antibodies directed against pro-inflammatory targets (anti-TNFalpha), antirheumatic drugs, analgesics, antimicrobials, corticosteroids, anabolic steroids, antidiabetics, thyroid agents, antidiarrheals, cough suppressants, antiemetics, antiulcers, laxatives, anticoagulants, erythropoietin, immunoglobulins, immunosuppressants, growth hormones, hormonal drugs, estrogen receptor modulators, alkylating agents, antimetabolites, mitotic inhibitors, radiopharmaceuticals, anti-depressants, antipsychotics, anxiolytics, hypnotics, sympathomimetics, stimulants, donepezil, tacrine, asthma drugs, beta-agonists, inhaled steroids, leukotriene inhibitors, cromoglycates or cromoglicic acids, epinephrine, alpha dornase, cytokines, cytokine antagonists.
[0088] Lastly, the present invention relates to a composition comprising, in a physiologically acceptable medium:
(1) (a) at least one bacterium selected from the group consisting of Christensenella timonensis, Christensenella minute, Christensenella massiliensis, Christensenella intestinihominis, and/or mixtures thereof; and/or (b) at least one culture supernatant of at least one bacterium selected from the group consisting of Christensenella timonensis, Christensenella minute, Christensenella massiliensis, Christensenella intestinihominis, and/or mixtures thereof; and (II) (a) at least one additional bacterium of the genus Akkermansia, more particularly of the species Akkermansia muciniphila; and/or (b) at least one culture supernatant of at least one additional bacterium of the genus Akkermansia, more particularly of the species Akkermansia muciniphila.
[0089] Method of prevention and/or treatment.
[0090] According to another aspect, the present invention relates to a method for reducing and/or preventing inflammation in an individual in need thereof, comprising administering an effective amount of a bacterium of the Christensenellaceae family to said individual, in particular a bacterium of the species Christensenella.
[0091] The invention also relates to a method for reducing the level of IL-6 and/or stabilizing the level of IL-6 and/or preventing an increase in the level of IL-6 in an individual in need thereof, comprising administering an effective amount of a bacterium of the Christensenellaceae family to said individual, in particular a bacterium of the species Christensenella, preferably said individual exhibiting elevated serum levels of IL-6 before the treatment. In particular, said elevated serum IL-6 levels are greater than 5 pg/ml, greater than 10 pg/ml, greater than 20 pg/ml, greater than 30 pg/ml, greater than 40 pg/ml, greater than 50 pg/ml, greater than 70 pg/ml, greater than 90 pg/ml or greater than 100 pg/ml.
[0092] The invention also relates to a method for reducing the level of IL-8 and/or stabilizing the level of IL-8 and/or preventing an increase in the level of IL-8 in an individual in need thereof, comprising administering an effective amount of a bacterium of the Christensenellaceae family to said individual, in particular a bacterium of the species Christensenella, preferably, said individual exhibiting elevated serum IL-8 levels before the treatment. In particular, said elevated serum IL-8 levels are greater than 5 pg/ml, greater than 10 pg/ml, greater than 20 pg/ml, greater than 30 pg/ml, greater than 40 pg/ml, greater than 50 pg/ml, greater than 70 pg/ml, greater than 90 pg/ml or greater than 100 pg/ml.
[0093] The invention also relates to a method for increasing the level of IL-10 and/or stabilizing the level of IL-10 and/or preventing a decrease in the level of IL-10 in an individual in need thereof, comprising administering an effective amount of a bacterium of the Christensenellaceae family to said individual, in particular a bacterium of the species Christensenella, preferably, said individual exhibiting low serum IL-10 levels before the treatment. In particular, said low serum IL-10 levels are less than 15 pg/ml, less than 10 pg/ml or less than 5 pg/ml.
[0094] In addition, the invention relates to a method for reducing the level of kynurenine and/or stabilizing the level of kynurenine and/or preventing an increase in the level of kynurenine in an individual in need thereof, comprising the administration of an effective amount of a bacterium of the Christensenellaceaefamily to said individual, in particular a bacterium of the species Christensenella, preferably, said individual exhibiting high levels of fecal kynurenine before the treatment.
[0095] The invention also relates to a method of treating and/or preventing cancer associated with inflammation in an individual in need thereof, comprising administering an effective amount of the Christensenellaceae bacteria to said individual.
[0096] The method according to the present invention makes it possible to reduce the level of at least one of the markers of inflammation mentioned above in said individual, said marker being preferably reduced in serum, blood or stool.
[0097] Preferably, the present methods are implemented in an individual suffering from one or more diseases described above in the specification, said individual preferably being a human being.
[0098] Preferably, the bacterium Christensenella comprises a 16S ribosomal RNA gene exhibiting a sequence identity of at least 50%, at least 60%, at least 70%, at least 80% or, preferably at least 90% with a 16S ribosomal RNA gene from Christensenella minute, Christensenella massiliensis, or Christensenella timonensis, more preferably at least 97% sequence identity with a sequence selected from SEQ ID NO: 1, 2, 3, 4, 5 or 6.
[0099] SEQ ID NO: 1 is a sequence of the 16S ribosomal RNA gene of the bacterium Christensenella minute DSM 22607, which was isolated from a human fecal sample. The
C. minuta 16S rRNA sequence is identified by the GenBank accession number AB490809. SEQ ID NO: 2 is part of the 16S ribosomal RNA gene sequence from the bacterium Christensenella minute DSM 22607. Additional 16S sequences for bacteria of the genus Christensenella, such as SEQ ID NOs: 3-6 (OTU numbers 701845, 177179, 1146771, and 361793 in the Greengenes database, respectively), are provided. The identity of each sequence with respect to SEQ ID NO: 1 is as follows: SEQ ID NO: 3, 93% identity with SEQ ID NO: 1; SEQ ID NO: 4, 95% identity with SEQ ID NO: 1; SEQ ID NO: 5, 97% identity with SEQ ID NO: 1; SEQ ID NO: 6, 95% identity with SEQ ID NO: 1.
[0100] In particular, said methods comprise the administration of at least one bacterium or composition according to the present invention, characterized by any of the embodiments described above, such as the mixture or not of the bacteria, the quantity administered, the amount of viable bacteria, the additional components, for example active pharmaceutical ingredients, prebiotics or probiotics, vitamins, minerals, nutritional agents, other microorganisms, the particular formulation of said composition, for example powder, capsule, etc.
[0101] Understandably, the present methods include oral, inhaled, topical, rectal or intrarectal administration in a sufficient amount.
[0102] The invention is now illustrated by examples of bacteria useful according to the invention, methods of culturing these bacteria, examples of compositions containing the same, and test results demonstrating the effectiveness of the invention which are shown for illustration purposes only.
[0103] EXAMPLES
[0104] Example 1: Christensenella minuta. Christensenella minute can be cultured according to the operating protocol described below. 1/ Dissolve a dehydrated RCM (Reinforced Clostridial Medium) in distilled water 2/ Add 0.5 mi/L of resazurin-Na solution (0.1% w/v) 3/ Bring to a boil and cool to room temperature while injecting a gas mixture of 80% N 2 and 20%CO 2
4/ Spread the medium under the same gaseous atmosphere in anoxic Hungate-type tubes or in vials of serum then autoclave 5/ Before use, add 1.0 g of sodium carbonate per liter from a sterile anoxic stock solution prepared with a gas mixture of 80% N 2 and 20%CO 2
6/ Check the pH of the medium after autoclaving and adjust the pH between 7.3 and 7.5, using a sterile anoxic stock solution of sodium bicarbonate (5% w/v) prepared in a gaseous atmosphere at 80% N 2 and 20%CO 2
[0105] Example 2: Christensenella massiliensis. Christensenella massiliensis can be cultured accordingto the operating protocol described below. 1/ Prepare a carboxymethylcellulose (N2/CO 2 ) medium by following the instructions below provided by DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen).
[0107] [Table 1]
Casitone 30.0 g
Yeast extract 5.0 g
K2HP0 4 5.0 g
Na-resazurin solution (0.1% w/v) 0.5 ml
L-Cysteine-HCI x H 20 0.5 g
D-Glucose 4.0 g
Cellobiose 1.0 g
Maltose 1.0 g Minced meat (fat free) 500.0 g NaOH 1N 25.0 ml
Distilled water 1000 ml
Starch (soluble) 1.0 g
Na 2CO 3 1.5 g
Meat filtrate (see Table 2) 1000 ml
[0108] 2/ Dissolve the various constituents listed in the table above, with the exception of cysteine, carbohydrates and carbonate. 3 /Boil the medium for 1 min, then let it cool to room temperature under a gaseous atmosphere at 80% N 2 and 20%CO 2
. 4/ Add 0.5 g/L L-cysteine-HCI x H 20 and pour it under the same gaseous atmosphere into Hungate-type tubes (for strains requiring meat particles, introduce these first into the tube, use 1 part meat particles for 4 or 5 parts liquid). / Autoclave at 121°C for 20 min. 6/ After autoclaving, add glucose, cellobiose, maltose and starch from sterile anoxic stock solutions prepared with 100% N 2 gas and carbonate from a sterile anoxic stock solution prepared under gas mixtures at 80 %N 2 and 20%CO 2
. 7/ Adjust the pH of the medium to 7, if necessary. Preparation of the meat filtrate:
[0109] [Table 2]
[0110] Use lean beef or horse meat. Remove fat and connective tissue before chopping. Mix the meat, water and NaOH, then boil for 15 min while stirring. Cool to room temperature, remove the fat from the surface and strain, retaining the meat particles and the filtrate. Add water to the filtrate to a final volume of 1000.0 ml. Bacteria should be cultured in anaerobic condition at 37 °C.
[0111] Example 3: Christensenella timonensis Christensenella timonensis can be cultured according to the same operating protocol as that described in Example 2 for Christensenellamassiliensis.
[0112] Example 4: Specific strains according to the invention All the strains described below were obtained from the German DSMZ collection (Leibnitz DSMZ Institute). Christensenella minute DSM 22607, Christensenella timonensis DSM 102800 and Akkermansia muciniphila DSM 22959 were cultured at 37 °C in YBHI medium
[brain-heart perfusion medium supplemented with 0.5% yeast extract (Difco)] supplemented with cellobiose (1 mg/ml; Sigma), maltose (1 mg/ml; Sigma), cysteine (0.5 mg/ml; Sigma) and mucin (1mg/ml; Sigma) in an anaerobic chamber filled with N 2 = %,CO2 =10%and H 2 =5%.
[0113] Example 5: Useful composition based on supernatants
An example of a composition useful according to the invention is a composition comprising between 0.1 and 95% culture supernatant of the strains Christensenella minute DSM 22607, Christensenella timonensis DSM 102800 and Akkermansia muciniphila DSM 22959.
[01141 Example 6: Composition in liquid form useful according to the invention An example of a composition in liquid form useful according to the invention is a composition comprising Christensenella minute 10' CFU/ml in the anaerobic RCM culture medium described above, modified to contain no animal by-product and enriched in 5% glycerol. The composition of Example 6, obtained from an RCB (Research Cell Bank), is prepared from 101 CFU/ml Christensenella minutethen stored frozen at -20 °C in a packet sealed off from oxygen. The frozen composition must be warmed to room temperature until it returns to a liquid form before use.
[0115] Example 7: Composition in solid form useful according to the invention An example of a composition in lyophilized form useful according to the invention may be obtained by lyophilization of the composition of Example 6 in the frozen state.
[0117] TEST RESULTS DEMONSTRATING THE EFFECT OF THE INVENTION
[0118] 1. Demonstration of the in vitro anti-inflammatory effect of Christensenella bacteria (kynurenine).
[0119] The objective of this study is to demonstrate the in vitro anti-inflammatory effect of Christensenella bacteria according to the invention. The demonstration of this effect was carried out on kynurenine, a known marker of inflammation. Human faeces were collected and cultured in a fermenter. The abundance of Christensenella spp. was correlated with the abundance of kynurenine present in the fermenter.
[0120] The operating protocol of the study is described below. 1/ Fermentation protocol from faeces of human origin containing Christensenella spp.: - Donors should not have taken antibiotics during the six months preceding the experiment and have no history of gastrointestinal disorders. The donors were between 18 and 60 years old. - Collection of fresh samples of their faeces is obtained in sterile plastic containers, kept in anaerobic vials containing an Oxoid' AnaeroGen' M 2.5 L sachet (02<0.1%; CO 2 : 7-15%). These samples were brought to the laboratory within two hours of production. - The faeces samples were diluted 1/5 (weight/volume) in phosphate buffered saline (IM) (PBS), pH 7.4. The suspension was homogenized in a stomacher for 120 seconds. - Basic nutrient medium: the basic nutrient medium was prepared from 2 g/L of soybean tryptone broth, 2 g/L yeast extract, 0.1 g/L NaCl, 0.04 g/L K2 HPO 4 , 0.01 g/LMgSO3.7H 20, 0.01 g/L CaCl 2.6H20, 2 g/L NaHCO 3, 0.5 g/L L-cystine HCI, 2m1/L tween 80, 10 l/L vitamin.K1, 0.05 g/L heme, 0.05 g/L bile salts, 4 m/L resazurin (pH7). - Fermentation in a biofermenter: The 20 ml biofermenters contained 18 ml of basic nutrient medium, autoclaved (121°C for 15 minutes) and poured aseptically into sterile biofermenters. This system was allowed to stand overnight with oxygen-free nitrogen bubbling through the medium at a rate of 2 ml/min. The pH was maintained between 6.7 and 6.9 using HCI or NaOH (0.5M). The temperature of each biofermenter was controlled at 37 °C and the contents of the container homogenized with a magnetic mixer. - A mixture of predigested proteins (0.35 g) was added to the containers before inoculation with 2 ml fecal inoculum at TO. The predigested proteins were obtained according to the gastrointestinal digestion protocol adapted from that of Versantvoort et al. (2005). - The samples were collected before fermentation (TO) and after 48 hours of fermentation (T48), and frozen at -80 °C until analyzes were carried out. 2/ Quantification of kynurenine - 50 pL of samples collected and stored at -80 °C were mixed with 20 pL of Milli Q water containing internal standards. - The mixture was mixed and filtered through a 5-kDa cutoff filter to remove macromolecules. - The metabolites were detected by capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS) analyzes. The peak detection limit was determined based on the signal-to-noise ratio, S/N=3. Relative peak area = (peak area of a metabolite):(peak area of internal standard x amount of sample). 3/ Quantification of Christensenella spp.
- The DNA contained in the samples was extracted using the NucleoSpin'96 Soil kit from Macherey-Nagel according to the manufacturer's instructions. -The total extracted DNA was then fragmented randomly into fragments of 350 bp then used to construct a library using the NEBNext Ultra II kit from New England Biolabs according to the manufacturer's instructions. - The library was then sequenced using 2 x 150 bp paired-end sequencing on an Illumina HiSeq platform. - The abundance of bacteria was measured by creating a catalog of metagenomic species (MGS) from a reference catalog containing 22M genes. These MGSs were then associated at an appropriate taxonomic level. In the case of Christensenella, these were detected at the genus-level and are therefore referenced in this experiment by Christensenella spp.
[0121] The relative amount of kynurenine (relative to the total amount measured) and the relative abundance of Christensenella spp. (relative to the total quantity measured) were analyzed and correlated, obtaining a linear regression of R=-0.44 (n=18). The results are shown in Table 3.
[0122] [Table 3]
Samples Relative abundance of Relative amount of kynurenine Christensenella spp. (x10-2 ) (x10-5 )
V1 7.55 0
V2 3.18 0
V3 8.19 0
V4 2.63 3.46
V5 1.26 3.67
V6 2.87 0
V7 7.20 8.18
V8 2.91 4.58
V9 6.32 0
V10 1.21 13.00
V11 4.23 14.19
12 1.49 8.36
V13 9.83 0
V14 4.12 2.87
V15 6.45 0
V16 2.02 5.30
V17 5.23 4.76
V18 7.57 2.92
[0123] 2. Demonstration of the in vitro anti-inflammatory effect of Christensenella bacteria (IL-8)
[0124] The objective of this study is to demonstrate the in vitro anti-inflammatory effect of bacteria according to Example 4. The demonstration was carried out on one of the markers of inflammation: interleukin 8 (IL-8).
[0125] The study is carried out on HT-29 cells obtained as follows: HT-29 (ATCC HTB-38) human colon epithelial cells (LGC Standards) were cultured in Dulbecco's Modified Eagle's minimum essential medium (DMEM) (Sigma-Aldrich) supplemented with 10% (w/v) thermo-activated fetal bovine serum (FBS) (GibcoBRL, Eragny, France) and penicillin G/streptomycin (5000lU/ml, 5000 .g/ml) (Sigma-Aldrich). Cell cultures were incubated in 25-cm 2tissue culture flasks (Nunc, Roskilde, Denmark) at 37 °C in a 5% (v/v) CO 2 atmosphere until confluence is reached.
[0126] The operating protocol of the study is described below.
[0127] The single cultures and the cocultures composed of the combinations between the listed strains are prepared at time 0. At 24 hours, the bacterial samples are centrifuged for 10 minutes at 6000 rpm. The supernatants thus obtained are stored at -80 °C in order to continue the analysis of the in vitro immunomodulatory properties.
[0128] Anti-inflammatory tests were carried out according to the procedure described by Kechaou et al., 2012 (Kechaou N et al.:Appl Environ Microbiol 2012, 79:1491-1499). Specifically, 50,000 HeLa or HT-29 cells per well were seeded in 24-well culture plates (Nunc). Twenty-four hours before the bacterial contact, the culture medium was replaced with a medium containing 5% FBS. The experiments were undertaken on the 7th day after seeding, when the cells were at confluence (1.8 3 x06 cells/well). Twenty-four hours before the bacterial coculture (day 6), the culture medium was replaced with a medium containing 5% heat-inactivated FBS and 1% glutamine. On the day of the coculture, 10% bacterial supernatant was added to the DMEM in a total volume of 5001.11. Cells were simultaneously stimulated with humanTNF-a (5 ng/ml; Peprotech, NJ)for6 hoursat37 °C in10% CO2 . All samples were analyzed in triplicate. After co-incubation, cell supernatants were collected and stored at -80 °C until ELISA (Biolegend, San Diego, CA) performed further analysis of interleukin-8 (IL-8). The experiments were carried out at least in triplicate.
[0129] FIG. 1 shows the production of IL-8 in HT-29 cells stimulated by TNF-a in the presence of Christensenella minute, Christensenella timonensis, Akkermansia muciniphila, Christensenella minute + Akkermansia muciniphila and Christensenella timonensis
+ Akkermansia muciniphila. The results are expressed in IL-8 (pg/mL) and were normalized using as reference value IL-8 produced after co-incubation with PBS as negative control. The results were analyzed using Kruskal Wallis test followed by Dunn's multiple comparison test (*p<0.05; **p<0.01).
[0130] GraphPad software (GraphPad Software, La Jolla, CA, USA) was used for the statistical analysis. The results are presented in the form of a boxplot (min. to max.). Comparisons were made with the Kruskal-Wallis nonparametric test followed by a Dunn's multiple comparison. A p-value less than 0.05 was considered significant.
[0131] The results are described below:
[0132] The reference strain Akkermansia muciniphila DSM 22959 is well known for its immunomodulatory properties and, more particularly, for its anti-inflammatory effects (Derrien M, Belzer C, de Vos WM. Microb Pathog. 2017 May; 106:171-181. doi: 10.1016/j.micpath.2016.02.005. Epub 2016 Feb. 11). To determine whether the strains of Christensenella minute DSM 22607 and Christensenella timonensis DSM 102800 are capable of modulating the immune response, the inventors tested in vitro the immunomodulatory properties of the supernatants of the strains in a model based on the ability to block the production of IL-8 (a pro-inflammatory cytokine) induced by TNF-a stimulation in HT-29 colon epithelial cells.
[0133] Thus, the inventors observed that the two strains are capable of blocking the production of IL-8 in the same way as our positive control (Akkermansia muciniphila DSMZ 22959) (FIG. 1).
[0134] Christensenella minute DSM 22607 and Christensenella timonensis DSM 102800 increase the anti-inflammatory properties of Akkermansia muciniphila DSMZ 22959 in vitro.
[0135] In order to test whether the members of Christensenella were able to increase the anti-inflammatory properties of other members of the intestinal microbiota, cocultures with Akkermansia muciniphila were carried out. As also shown in FIG. 1, Christensenella minute DSM 22607 and Christensenella timonensis DSM 102800 were able to increase the anti-inflammatory properties of Akkermansia muciniphila DSMZ 22959 in a statistically significant manner.
[0136] 3. Demonstration of the in vitro anti-inflammatory effect of Christensenella bacteria (IL-8).
[0137] The objective of this study is to demonstrate the anti-inflammatory effect in vitro of bacteria according to the invention. The demonstration was carried out on one of the markers of inflammation: interleukin-8.
[0138] The operating protocol for the study is described below.
[0139] When the HT-29 cells are at confluence (approximately 7 days after seeding), the complete medium (DMEM Glutamax + 10% FCS) is then removed in order to be replaced by medium containing 5% FCS (DO). On D+1, the medium is removed. Two media (DMEM Glutamax + 5% FCS +/- TNF-a) are prepared. 450 pL/well of one of the two media are then added, followed by 50 pL of the supernatants to be tested. After 6 hours of co-incubation, the supernatants are recovered and stored at -80°C. IL-8 chemokine ELISA assays are then carried out (ELISA MAX Deluxe set Human IL-8 from Biolegend).
[0140] FIG. 2 shows the assay of the chemokine IL-8 secreted by HT-29 cells (colon adenocarcinomas) in an inflammatory state induced by TNF-a. Different bacterial supernatants (C. minute 1, C. minute 2, C. minute 3, C. minute 4 and DSMZ, corresponding to strain DSM22607) belonging to bacteria of the species Christensenella minute were tested in order to evaluate their immunomodulatory capacity. The bacterial culture medium (GAM) represents the control making it possible to assess the effects of the supernatants. The experiment was carried out four times in triplicate.
[0141] All the strains of Christensenella minute tested have an anti-inflammatory immunomodulatory effect (reduction of more than 50% in the level of IL-8 secreted), which makes it possible to confirm the anti-inflammatory potential of Christensenella.
[0142] 4. Demonstration of the effect of Christensenella bacteria on the permeability of the intestinal epithelial membrane.
[0143] FIG. 3 represents the measurement of the transepithelial electrical resistance taken on Caco-2 epithelial cells. The latter establish junctions (called tight junctions) between them by differentiating, allowing to maintain the integrity of this barrier created by the cells, mimicking the intestinal barrier present in our digestive tract.
[0144] The addition of the cytokine TNF-a (Tumor Necrosis Factor) disrupts these tight junctions then increases membrane permeability, promoting, for example, inflammatory or infectious diseases and thus reducing the TEER ratio (DMEM + TNF- control group). The "DMEM" control group represents the wells where only the cell culture medium was present, without TNF-a or bacteria.
[0145] Transepithelial electrical resistance (TEER) is a method for quantifying the integrity of the barrier of epithelial tissue by measuring the electrical resistance therethrough. TEER measurements are performed by placing electrodes at both poles of a layer of epithelial cells that have been cultured on a semi-permeable membrane. The electrodes apply an alternating current allowing the measurement of the electrical resistance through the layer of epithelial cells.
[0146] The TEER ratio is obtained by the following calculation:
TEER treatment t24 /TEER treatment tO TEER ratio =-----------------
TEER control t24 /TEER control tO
[0147] 7 days after seeding of Caco-2 cells (intestinal epithelial cells) in Transwell plates, the TEER is measured using an automated machine (REMS). The values are recorded and represent our starting value (TO). The cells are then co-incubated in the presence of bacteria in (MOI 1/40) for 3 hours, the time for the latter to adhere to the cells. The cells are then challenged with TNF-a inducing a disruption of the epithelial cell layer, in particular at the tight junctions. 24 hours (T24) after adding the bacteria, the TEER is measured again.
[0148] This figure shows that the Christensenella minuta bacteria influence the integrity of the intestinal barrier by improving transepithelial resistance, indicating a potential effect on tight junction proteins and a decrease in intestinal permeability. Therefore, the Christensenella minutebacteria make it possible to restore the resistance of the epithelial membrane.
[0149] 5. Demonstration of the in vivo anti-inflammatory effect of Christensenella bacteria
[0150] The objective of this study is to demonstrate the in vivo anti-inflammatory effect on mice, of bacteria according to the invention. The demonstration was carried out on major markers of inflammation, two cytokines: IL-6 (interleukin 6) and TNF-a (Tumor Necrosis Factor- alpha). The study was carried out as a blind study: the experimenters did not know the treatments so that their previous knowledge did not influence the result of the study in any way.
[0151] The operating protocol is described below. - Four-week old C57BL/6 male mice were purchased from Charles River (St Germain sur l'Arbresle, France). - The mice had a one-week period of acclimatization on the diet based on a standard diet ("chow diet (SafeA04)") before starting the study. - On the first day (DO), the animals were subjected to a diet rich in fat (45% kcal "Research Diet D12451") and distributed randomly into 2 groups (n = 5 per group), each receiving either a solution of 150 pL of Christensenella minute (10' CFU/mL), i.e., a control solution consisting of the culture medium used for the growth of bacteria for 12 weeks. The animals were provided with food and water at will throughout the duration of the study and were kept in a room at controlled temperature (22.0±2.0 °C) and humidity (40-50 %) and on a cycle of 12 hours of light (8 a.m. to 8 p.m.)/12 hours of darkness. - At the end of the experiment (D85), the last blood samples were taken from the anesthetized animals (with a mixture of ketamine/xylazine 80/10 mg/kg). Blood samples were collected in centrifuge tubes pre-filled with heparin sulfate (200 lU/ml blood). The plasma was separated by centrifugation (3500 rpm, 15 min., 4 C), collected and then stored at -80 °C until analysis. - The plasma levels of cytokines IL-6 and TNF-a were determined using the "Invitrogen* Luminex* Cytokine Mouse Magnetic 10-Plex" ELISA assay kit and according to the manufacturer's instructions. The measurements were carried out by VEBIO (Arcueil, France).
[0152] The assay results (presented in Table 4) of the pro-inflammatory cytokines TNF-a and IL-6 after 85 days of a high-fat diet at 45% (cal) show that a bacterium of the Christensenellaceae family strongly limits inflammation.
[Table 4] Diet Mouse TNF-a Mean IL-6 Mean (pg/mL) TNF-a+/- (pg/mL) IL-6 +/- SEM SEM C9-SM 44.61+/ 62.48 11.40 HFD45%+ C9-OG 17.00 C. minuta C15-SM 52.17 C15-OG 72.73 C15-OD 18.68 C12-SM 2.93 3.53+/- 89.71 117.25 +/ C12-OG 0.36 144.76 28.57 HFD45% + C12-OD 4.19 39.96 control C14-SM 3.49 101.85 C14-OG 1.87 209.96
[0153] 6. Demonstration of the in vivo anti-inflammatory effect of Christensenella bacteria
[0154] As soon as they arrive, the animals are put in a cage (n=5 per cage) and start an acclimatization period in order to allow the mice to recover from transport and reduce stress by getting used to this new environment. After one week, gavage of all groups (except the 5-ASA control group, pharmacological anti-inflammatory control) as well as weight monitoring begin. The control mice (ctr-vehicle and DNBS-vehicle) are gavaged with 150 pL of PBS/16% glycerol. The DNBS-Christensenella minuta (C. minuta) mice are gavaged with 150 pL of C. minuta DSM 22607 at 1010 CFU/mL resuspended in PBS/16% glycerol. After two weeks, inflammation is induced by means of a chemical called DNBS (dinitrobenzensulfate). The latter is injected directly into the colon of the mouse by a probe introduced into the rectum. DNBS is dissolved in 30% ethanol, making it possible to weaken the intestinal barrier to facilitate the entry of DNBS into the tissue, thus triggering the immune system and therefore inflammation. The gavages continue during this period, and those of the 5-ASA group begin on the day of this injection at 150 pL (solution of 5 ASA prepared every morning, at 2 mg/mouse resuspended in PBS). Euthanasia takes place 3 days after the injection. The so-called "recovery" period is therefore short, but necessary to be able to observe differences with the DNBS control group.
[0155] FIG. 4 shows the various parameters evaluated during a test on an inflammatory model induced by DNBS.
[0156] In FIG. 4A, the monitoring of the weight loss was observed from the day of the injection, and therefore the recovery period (D1, D2 and D3) which follows. The inventors have thus observed an effect on the recovery which seems to be faster after the administration of the treatment.
[0157] In FIG. 4B, the macroscopic scores show the level of severity of the disease, indicate that following the treatments with DSM 22607, a significant decrease in the score was observed, also observed with the pharmacological anti-inflammatory agent, 5-ASA (5 aminosalicylic acid used as a comparative positive control).
[0158] FIGs. 4C and 4D show the immunomodulatory potential of DSM 22607, in particular by reducing the presence of neutrophils in the colon, evaluated by monitoring the activity of myeloperoxidase. In addition, the increase in interleukin-10 in the spleen (FIG. 4D) shows the anti-inflammatory effects associated with Christensenella minute.
[0159] 7. Demonstration of the in vivo anti-inflammatory effect of Christensenella bacteria
[0160] Three days after the injection, the animals are euthanized. The change in the weight of the mice is measured by taking the weight of the mice daily. During the sacrifice, the colon is opened and cleaned in order to carry out the macroscopic score. The latter is based on the presence of blood in the tissue (hyperemia), the presence of ulcer, the intestinal transit (for example if the mouse was constipated) and the thickening of the colon induced by DNBS.
[0161] Apiece of colon is also recovered in order to assay the activity of myeloperoxidase (MPO). This enzyme is present in neutrophils, markers of inflammation. It also participates in the production of reactive oxygen species (ROS). During this test, after weighing the colon to normalize the results according to the size of the sample, a calorimetric reaction takes place to measure the activity of this enzyme.
[0162] The spleen is also recovered during the sacrifice (peripheral lymphoid organ) and the cells of the innate and adaptive immune response are stimulated in order to assay the secreted cytokines such as IL-10, anti-inflammatory cytokines.
[0163] FIG. 5 shows the effects of other strains of Christensenella minute during a repetition of the experiment presented in FIG. 4. The experimental design and the methods remain similar. This experience teaches us that all the strains of Christensenella minute tested have the same efficacy in reducing macroscopic scores following intrarectal injection of DNBS. Likewise, all the strains tested show an anti-inflammatory effect which results in a reduction in MPO activity.
[0164] 8. Demonstration of the anti-proliferative effect of Christensenella bacteria
[0165] The HT-29 cells were inoculated at a density of 10,000 cells/well in a total volume of 100 pl in a 96-well plate. After 24 hours of incubation, the culture medium was removed from the adherent cells and new medium supplemented with 10% Christensenella minuta stationary phase supernatant was added (DSMZ, C. minute 1 and C. minute 2 and in control GAM (bacterial culture medium)). Each condition was performed in 4 replicates. The cells were incubated for an additional 48 or 72 hours.
[0166] Cell proliferation was determined by means of the CellTiter-Glo 2.0 assay kit (Promega). The measurements were carried out according to the manufacturer's instructions. Briefly, the plates were removed from the incubator and allowed to equilibrate at room temperature for 30 min and an equal volume of CellTiter-Glo 2.0 reagent was added directly into the wells (100 Ipl). The plates were stirred at 300 rpm for 2 min using a rotary shaker, then incubated at room temperature for 10 min. The reaction mixture was then transferred to a white-walled 96-well plate and the luminescent signal was measured using a microplate reader (FLUOstar Omega, BMG Labtech).
[0167] FIG. 6 shows the influence of strains of Christensenella minute on the proliferation of tumor cells.
[0168] The inventors observed the influence of strains of Christensenella minute on the proliferation of tumor cells. We analyzed the effect of these supernatants by treating a human colon adenocarcinoma cell line, the HT-29 line. The effect of the supernatants of Christensenella minute on the proliferation of HT-29 cells was evaluated after 48 hours and 72 hours. The supernatants of strains DSM22607 (DSMZ), C. minute 1 and C. minute 2 significantly reduce the proliferation of the cells treated for 48 hours and 72 hours, compared to the "GAM" control, corresponding to the cells treated with the bacterial culture medium (Statistical test = Dunnett where the control group is the GAM; ****GAM vs DSMZ p<0.0001, *GAM vs C.minuta1 p=0.0140, **GAM vs C. minute 2 p=0.0027 at 48 hours and ****p<0.0001 at 72 hours). Akt inhibitor Vill is used as a control for blocking cell proliferation.
[0169] This experiment makes it possible to conclude that the supernatants of the different strains of Christensenella minute tested induce a decrease in the proliferation of the HT-29 tumor line, and therefore that these strains play a role in the inhibition of tumor development.
Claims (22)
- 35 CAF-100203AU-11092021claims[Claim 1] A bacterium of the genus Christensenella for use in the prevention and/or treatment ofchronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers in humans or animals.
- [Claim 2] The bacterium of the genus Christensenella for its use according to claim 1, in patients ornimals exhibiting hyperproduction of interleukin 6 and/or interleukin 8 and/or underproduction of interleukin 10.
- [Claim 3] The bacterium of the genus Christensenella for its use according to one of the precedingaims, in the treatment of at least one disease selected from chronic inflammatory bowel diseases, chronicflammatory diseases of the liver, chronic inflammatory diseases of the pancreas, polyarthritis, atopic dermatitis,euroinflammatory diseases, chronic obstructive pulmonary disease and inflammatory bowel diseases.
- [Claim 4] The bacterium of the genus Christensenella for its use according to the preceding claim, ithe treatment of at least one disease selected from Crohn's disease, ulcerative colitis, pouchitis, ulcerative colitis,eliac disease, autoimmune gastritis, hepatitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, ancreatitis, rheumatoid arthritis, psoriatic arthritis, psoriasis and eczema.
- [Claim 5] The bacterium of the genus Christensenella for its use according to one of claims 1 or 2, >r use in the treatment of lymphomas, glioblastomas, myelomas, leukemias, colorectal cancers, breast cancers,dancers prostate, ovarian cancer, uterine cancer, pancreatic cancer, lung cancer, liver cancer, gallbladder cancer anddney cancer.
- [Claim 6] The bacterium of the genus Christensenella for its use according to one of the precedingaims, characterized in that said bacterium is selected from Christensenella massiliensis, Christensenella timonensis,hristensenella intestinihominis, and Christensenella minute.
- [Claim 7] A composition comprising at least one bacterium of the genus Christensenella accordingone of the preceding claims in a physiologically acceptable medium and/or a culture supernatant of at least one acterial strain of the genus Christensenella for use in the prevention and/or the treatment of chronic inflammatoryiseases and/or inflammatory gastrointestinal diseases and/or cancers.
- [Claim 8] The composition for its use according to claim 7, wherein said bacterium of the genushristensenella and said culture supernatant may comprise or be derived from the same or different strains or speciesf Christensenella.
- [Claim 9] The composition for its use according to one of claims 7 or 8, said composition beingadministered to a human having a body mass index of less than 25.
- [Claim 10] The composition for its use according to one of claims 7 or 9, characterized in that saidacterium is selected from Christensenella massiliensis, Christensenella timonensis and Christensenella minute and/orfixtures thereof.36 CAF-100203AU-11092021
- [Claim 11] The composition for its use according to one of claims 7 to 10, characterized in that atast 50% of the bacteria present are living bacteria (by number).
- [Claim 12] The composition for its use according to one of claims 7 to 11, characterized in that atast 90% of the bacteria present are living bacteria (by number).
- [Claim 13] The composition for its use according to one of claims 7 to 12, further comprising:at least one additional bacterium of the Verrucomicrobiaceaefamily; and/ori) a culture supernatant of said additional bacterium.
- [Claim 14] The composition for its use according to claim 13, wherein the additional bacterial straina bacterium of the genus Akkermansia, more particularly of the species Akkermansia muciniphila.
- [Claim 15] The composition for its use according to one of claims 7 to 14, characterized in that it is rovided in liquid form or in solid form.
- [Claim 16] The composition for its use according to claim 15, characterized in that the compositionsolid form comprises said bacteria inlyophilized form.
- [Claim 17] The composition for its use according to one of claims 7 to 16, wherein the compositionadministered orally, rectally, inhaled or topically.
- [Claim 18] The composition for its use according to one of claims 7 to 17, characterized in that it isthe form of powder, microencapsulated powder, gelatin capsule, capsule, tablet,lozenge, granules, emulsion,ispension, suppository, a beverage, a food, pharmaceutical or nutraceutical product, a food additive, dietaryipplement or dairy product.
- [Claim 19] The composition for its use according to one of claims 7 to 18, characterized in that it isa gastro-resistant form.
- [Claim 20] The composition for its use according to one of claims 7 to 19, characterized in that it omprises at least one probiotic and/or at least one prebiotic.
- [Claim 21] The composition for its use according to one of claims 7 to 20, characterized in that itso comprises:- at least one probiotic, and/or- at least one bacterium producing lactic acid and/or at least one other organism promoting the anaerobicconditions necessary for the survival of Christensenellaceae, and/or- at least one bacterium associated with the ecosystem of Christensenellaceae,and/or- at least one bacterium selected from bacteria of the genus Faecalibacterium,Akkermansia, Eubacterium andOscillospira, and/or- at least one prebiotic, and/or- at least one polyphenol, and/or37 CAF-100203AU-11092021- at least one mineral and/or at least one vitamin, and/or at least one nutritional agent, and/or- at least one active pharmaceutical principle preferably selected from non-steroidal anti-inflammatory drugs,antibodies directed against pro-inflammatory targets (anti-TNFalpha, anti-IL-6, anti-IL-8), antirheumatic drugs,analgesics, antimicrobials , corticosteroids, anabolic steroids, antidiabetics, thyroid agents, antidiarrheals, coughsuppressants, antiemetics, antiulcers, laxatives, anticoagulants, erythropoietin, immunoglobulins, immunosuppressants, growth hormones, hormonal drugs, estrogen receptor modulators, alkylating agents,antimetabolites, mitotic inhibitors, radiopharmaceuticals, anti-depressants, antipsychotics, anxiolytics, hypnotics, sympathomimetics, stimulants, donepezil, tacrine, asthma medications, beta agonists, inhaledsteroids, leukotriene inhibitors, cromoglycates or cromoglycidic acids, epinephrine, alpha dornase, cytokines,cytokine antagonists, interleukin 10 agonists.
- [Claim 22] A composition comprising, in a physiologically acceptable medium:(I) (a) at least one bacterial strain selected from the group consisting of Christensenella timonensis,Christensenella minute and/or mixtures thereof; and/or(b) at least one culture supernatant of at least one bacterial strain selected fromthe group consisting of Christensenella timonensis, Christensenella minute and/or mixtures thereof;and(II) (a) at least one additional bacterial strain of the genus Akkermansia, more particularly of the speciesAkkermansia muciniphila;and/or(b) at least one culture supernatant of at least one additional bacterial strain of the genus Akkermansia, moreparticularly of the species Akkermansia muciniphila.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962816539P | 2019-03-11 | 2019-03-11 | |
FR1902437 | 2019-03-11 | ||
US62816539 | 2019-03-11 | ||
FR1902437A FR3093642A1 (en) | 2019-03-11 | 2019-03-11 | Bacteria of the Christensenellaceae family in the prevention and / or treatment of chronic inflammatory diseases and / or cancers |
FR1908384A FR3099054A1 (en) | 2019-07-24 | 2019-07-24 | Christensenella strain for use in the treatment and prevention of gastrointestinal inflammation |
FR1908384 | 2019-07-24 | ||
PCT/EP2020/056565 WO2020182916A1 (en) | 2019-03-11 | 2020-03-11 | Bacterium of the christensenellaceae family for the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2020235358A1 true AU2020235358A1 (en) | 2021-10-07 |
Family
ID=77922950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2020235358A Pending AU2020235358A1 (en) | 2019-03-11 | 2020-03-11 | Bacterium of the Christensenellaceae Family For The Prevention And/Or Treatment Of Chronic Inflammatory Diseases And/Or Inflammatory Gastrointestinal Diseases And/Or Cancers |
Country Status (5)
Country | Link |
---|---|
KR (1) | KR20210141541A (en) |
CN (1) | CN113631174A (en) |
AU (1) | AU2020235358A1 (en) |
CA (1) | CA3132239A1 (en) |
SG (1) | SG11202109872SA (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114159477B (en) * | 2021-11-24 | 2023-06-30 | 暨南大学 | Probiotic preparation for improving enteritis-induced male reproductive injury and application thereof |
CN113975301B (en) * | 2021-11-24 | 2023-06-30 | 暨南大学 | Probiotic preparation for improving sperm motility and application thereof |
WO2024140860A1 (en) * | 2022-12-27 | 2024-07-04 | 慕恩(广州)生物科技有限公司 | Use of christensenella sp. or composition comprising same in prevention or treatment of tumors, and drug comprising same |
CN116919994B (en) * | 2023-09-15 | 2023-12-08 | 中国农业大学 | Application of Klebsiella minutissima Teng Senshi bacteria in preparation of medicine for treating polycystic ovary syndrome |
CN117298155A (en) * | 2023-09-28 | 2023-12-29 | 善恩康生物科技(苏州)有限公司 | Application of Akkermansia muciniphila in preparation of product for preventing, treating and/or assisting in treating male reproductive injury |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016156527A1 (en) * | 2015-03-31 | 2016-10-06 | International Nutrition Research Company | Composition for the treatment of a pathogenic metabolic state of the intestinal microbiota and of derived diseases |
FR3034317B1 (en) * | 2015-03-31 | 2018-09-14 | International Nutrition Research Company | COMPOSITION FOR THE TREATMENT OF A PATHOGENIC METABOLIC STATE OF THE INTESTINAL MICROBIOTE AND DERIVED DISEASES |
US20180147221A1 (en) * | 2015-04-23 | 2018-05-31 | Kaleido Biosciences, Inc. | Glycan therapeutic compositions and related methods thereof |
JP2018534277A (en) * | 2015-10-05 | 2018-11-22 | シュヴァイツェリッシェ フォルシュングスインスティテュート フュア ホーフゲブリクスクリーマ ウント メディツィン イン ダヴォス | Use of Akkermansia muciniphila for treating inflammatory conditions |
EP3442545A4 (en) * | 2016-04-11 | 2020-01-08 | President and Fellows of Harvard College | Probiotic formulations for improving athletic performance |
FR3063646B1 (en) * | 2017-03-10 | 2021-07-30 | International Nutrition Res Company | BACTERIA SPECIFIC FOR THEIR USE AS A MEDICINAL PRODUCT, IN PARTICULAR FOR THE CONTROL OF OVERWEIGHT, OBESITY, CARDIOMETABOLIC DISEASES AND INFLAMMATORY DISEASES OF THE INTESTINE |
-
2020
- 2020-03-11 CA CA3132239A patent/CA3132239A1/en active Pending
- 2020-03-11 KR KR1020217032626A patent/KR20210141541A/en unknown
- 2020-03-11 SG SG11202109872S patent/SG11202109872SA/en unknown
- 2020-03-11 AU AU2020235358A patent/AU2020235358A1/en active Pending
- 2020-03-11 CN CN202080024667.9A patent/CN113631174A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210141541A (en) | 2021-11-23 |
CA3132239A1 (en) | 2020-09-17 |
CN113631174A (en) | 2021-11-09 |
SG11202109872SA (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230167401A1 (en) | Bacterium of the christensenellaceae family for the prevention and/or treatment of chronic inflammatory diseases and/or inflammatory gastrointestinal diseases and/or cancers | |
AU2020235358A1 (en) | Bacterium of the Christensenellaceae Family For The Prevention And/Or Treatment Of Chronic Inflammatory Diseases And/Or Inflammatory Gastrointestinal Diseases And/Or Cancers | |
CN114410548B (en) | Novel lactobacillus having various functions and use thereof | |
Sekhon et al. | Prebiotics, probiotics and synbiotics: an overview. | |
RU2563525C2 (en) | Probiotic composition for application in treatment of intestinal inflammation | |
CA2837479C (en) | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes | |
CA2774557C (en) | Lactobacillus plantarum strains as hypocholesterolemic agents | |
AU2017211244B2 (en) | Faecalibacterium prausnitzii strain CNCM 1-4573 for the treatment and prevention of gastrointestinal inflammation | |
KR102084825B1 (en) | Probiotic for infantile excessive crying | |
Quigley | Probiotics in gastrointestinal disorders | |
US20220339207A1 (en) | Faecalibacterium prausnitzii and christensenella bacterial strains for the treatment and prevention of bowel inflammation | |
CN117866831A (en) | Lactobacillus rhamnosus and application thereof | |
US11452747B2 (en) | Compositions of oligofructose and commensal microorganisms and methods thereof | |
Karakan | 13 Application of Functional Dairy Products from IBS to IBD | |
CA3089366A1 (en) | Composition comprising new lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections | |
Robles-Alonso et al. | Probiotics—From Gut to Cognition |